Literature DB >> 30847692

The synergistic effect of mefenamic acid with ionizing radiation in colon cancer.

Seyed Jalal Hosseinimehr1, Zahar Safavi2, Sahar Kangarani Farahani2, Zohreh Noaparst2, Arash Ghasemi3, Hossein Asgarian-Omran4,5.   

Abstract

Despite radiotherapy is an effective regimen in cancer treatment, resistance to tumor therapy still is a major challenge to radiotherapy and results in cancer recurrence and metastasis. Then the sensitization of tumor cells to ionizing radiation (IR) would be beneficial in cancer treatment. The aim of this study was to evaluate the synergistic effect of mefenamic acid (MEF) on colon cancer cell (HT-29) exposure to IR. HT-29 cells were treated with MEF and then exposed to IR. The synergistic effect of MEF is evaluated by clonogenic assay and flow cytometry. The productions of reactive oxygen species (ROS) were determined in irradiated and treated cells with MEF. The findings of this study showed that MEF had anti-cancer effect on colon cancer cell line and it increased the apoptosis in irradiated HT-29 cells. Also MEF reduced the number of cell colonies when HT-29 cells pre-treated with MEF and irradiated. MEF increased ROS production in irradiated cells. This additive effect of MEF with IR in killing of HT-29 cell was observed at low (10 μM) and medium (100 μM) concentrations of MEF. The present study demonstrates that MEF to be an additive effect on apoptosis and cell death induced by IR in colon cancer cells.

Entities:  

Keywords:  Apoptosis; Ionizing radiation; Mefenamic acid; Synergistic, radiosensitizing

Mesh:

Substances:

Year:  2019        PMID: 30847692     DOI: 10.1007/s10863-019-09792-w

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  33 in total

1.  Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals.

Authors:  M Asanuma; S Nishibayashi-Asanuma; I Miyazaki; M Kohno; N Ogawa
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

2.  A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: application to pharmacokinetic study.

Authors:  Mahadeo Mahadik; Sunil Dhaneshwar; Ravindra Bhavsar
Journal:  Biomed Chromatogr       Date:  2012-01-24       Impact factor: 1.902

Review 3.  Trends in the development of radioprotective agents.

Authors:  Seyed Jalal Hosseinimehr
Journal:  Drug Discov Today       Date:  2007-09-10       Impact factor: 7.851

Review 4.  Cellular redox pathways as a therapeutic target in the treatment of cancer.

Authors:  Alberto J Montero; Jacek Jassem
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

5.  Neuroprotection by mefenamic acid against D-serine: involvement of oxidative stress, inflammation and apoptosis.

Authors:  Guliz Armagan; Ezgi Turunc; Lutfiye Kanit; Ayfer Yalcin
Journal:  Free Radic Res       Date:  2012-03-16

Review 6.  Flavonoids and genomic instability induced by ionizing radiation.

Authors:  Seyed Jalal Hosseinimehr
Journal:  Drug Discov Today       Date:  2010-10-07       Impact factor: 7.851

Review 7.  DNA double strand break repair in mammalian cells.

Authors:  P Karran
Journal:  Curr Opin Genet Dev       Date:  2000-04       Impact factor: 5.578

8.  Mefenamic acid-induced apoptosis in human liver cancer cell-lines through caspase-3 pathway.

Authors:  Dong Ho Woo; In-Seob Han; Guhung Jung
Journal:  Life Sci       Date:  2004-10-01       Impact factor: 5.037

9.  Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid.

Authors:  Jeffery J Prusakiewicz; Kelsey C Duggan; Carol A Rouzer; Lawrence J Marnett
Journal:  Biochemistry       Date:  2009-08-11       Impact factor: 3.162

10.  Effects of ectopic HER-2/neu gene expression on the COX-2/PGE2/P450arom signaling pathway in endometrial carcinoma cells: HER-2/neu gene expression in endometrial carcinoma cells.

Authors:  Shu Li; XiaoXin Ma; Li Ma; Cuicui Wang; YuanQi He; ZhiJuan Yu
Journal:  J Exp Clin Cancer Res       Date:  2013-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.